Watchlist Price Alert

MoonLake Immunotherapeuti... (MLTX)

NASDAQ: MLTX · Real-Time Price · USD

44.91

1.41 (3.24%)

At close: Jun 23, 2025, 3:59 PM

45.99

2.40%

Pre-market: Jun 24, 2025, 07:26 AM EDT

3.24% (1D)

Bid	44.96
Market Cap	2.85B
Revenue (ttm)	101.85K
Net Income (ttm)	-145.51M
EPS (ttm)	-2.3
PE Ratio (ttm)	-19.53
Forward PE	-11.95
Analyst	Buy

Ask	46
Volume	352,019
Avg. Volume (20D)	521,617
Open	43.41
Previous Close	43.50
Day's Range	43.04 - 44.91
52-Week Range	31.42 - 58.26
Beta	1.23

About MLTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MLTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MLTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

+17.95%

MoonLake Immunotherapeutics shares are trading hig... Unlock content with Pro Subscription

3 weeks ago

+5.51%

MoonLake Immunotherapeutics shares are trading higher following reports that Merck held talks to acquire the Swiss biotech company for over $3 billion.

News

2 weeks ago · zacks.com

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

2 weeks ago · seekingalpha.com

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

MoonLake Immunotherapeutics completed enrollment of the two phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is...

3 weeks ago · reuters.com

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

1 month ago · zacks.com

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

The consensus price target hints at a 106.6% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

2 months ago · seekingalpha.com

MoonLake Immunotherapeutics: A Buy At Dips

MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials, yet faced a significant stock drop due to institutional sell-offs. Despite mixed r...